A new era for radiolabeled antibodies in cancer?

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 563-569

  Denardo, Sally J ^a   Kroger, Linda A ^a   Denardo, Gerald L ^a  

^a Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ADVANCED CANCER; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; LYMPHOMA; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; TUMOR CELL;

EID: 0032844393     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00017-5     Document Type: Review

References (52)

1. Zuckier LS, DeNardo GL Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med. 27:1997;10-29.
2. DeNardo GL, O'Donnell RT, Oldham RK, DeNardo SJ A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 13:1998;213-223.
3. Farah RA, Clinchy B, Herrera L, Vitetta ES The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryotic Gene Expr. 8:1998;321-356.
4. DeNardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, DeNardo DA, Kroger LA, Lamborn KR, Hellstrom KE, Hellstrom I, DeNardo GL Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 17:1997;1745-1752.
5. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med. 38:1997;1180-1185.
6. •] describe current effective studies of RIT in breast cancer, with PBSC support.
7. •].
8. •].
9. Meredith RF, Alvarez R, Khazaeli MB, LoBuglio A Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177Lu-CC49. Minerva Biotechnologica. 10:1998;100-107. This paper describes the first RIT/Taxol combination in patients with ovarian cancer.
10. Nicholson S, Gooden CSR, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF, Epenetos AA Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncology Rep. 5:1998;223-226. This article demonstrates statistically significant, enhanced survival that is associated with the use of RIT as an adjuvant in ovarian cancer therapy.
11. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, Peng J-S, McGahan JP Treatment of a patient with B cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers. 2:1987;49-53.
12. DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL Treatment of B cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer. 3(suppl 3):1988;96-101.
13. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher Set al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 14:1996;1974-1981.
14. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M Grillo-Lopez, AJ Chinn, P Varns, C Ning S-Cet al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 2:1996;457-470.
15. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 87:1996;3640-3649.
16. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:1995;336-340.
17. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko GM, Fisher LD, Porter Bet al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 329:1993;1219-1224.
18. Vose J, Saleh M, Lister A, Rohatiner A, Knox S, Radford J, Zelenetz AD, Stagg R, Tidmarsh G, Wahl R, Kaminiski MS Iodine-131 Anti-B1 antibody for non-Hodgkin's lymphoma (NHL): overall clinical trial experience [abstract]. Proc Am Soc Clin Oncol. 17:1998;10.
19. Kaminski MS, Gribbin T, Estes J, Ross CW, Regan D, Zasadny K, Tamminen J, Kison P, Tuck M, Fisher Set al. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions [abstract]. Proc Am Soc Clin Oncol. 17:1998;2. The authors report the first use of RIT for previously untreated lymphoma and demonstrate uniquely high response rates.
20. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin Cancer Res. 1999;. in press.
21. 131I-Lym-1 antibody. Cancer Biother Radiopharm. 13:1998;239-254.
22. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 16:1998;3246-3256. The authors demonstrate that >50% of heavily pretreated lymphoma patients showed at least a PR after the first of several RIT doses; all three patients given the MTD had CRs with non-myeloablative doses.
23. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Cancer. 80(suppl 12):1997;2706-2711.
24. Feldman E, Kalaycio M, Schulman P, Frankel S, Weiner G, Schwatzberg L, Velez-Garcia E, Jurcic J, Scheinberg D, Wedel N Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a phase II study [abstract]. Proc Am Soc Clin Oncol. 18:1999;4.
25. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WHJ, Geerlings MW, Warrell RPJ, Larson SM, Scheinberg DA Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 55(suppl 23):1995;5908-5910.
26. 90Y-HuM195 will be useful as part of a pretransplant regimen for the ablation of leukemia.
27. ••] report the first studies to show that targeted α-particle therapy is feasible in humans and provide targeting ratios (comparing tumors with whole-body doses) that are 1000-10,000-times those calculated for β-emitting nuclides in leukemia patients.
28. ••].
29. 90Y-labeled CO10-1A Fab' fragments in a human colonic cancer model. Cancer Res. 59:1999;2635-2643. This preclinical study demonstrates surprisingly effective therapy with α-particle-targeted RIT.
30. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Yet al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 320:1989;822-828.
31. Lichter AS, Lippman ME, Danforth DNJ, D'Angelo T, Steinberg SM, DeMoss E, MacDonald HD, Reichert CM, Merino M, Swain SMet al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol. 10:1992;976-983.
32. Sarrazin D, Le MG, Arriagada R, Contesso G, Fontaine F, Spielmann M, Rochard F, LeChevalier T, Lacour J Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 14:1989;177-184.
33. van Dongen JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, van der Schueren E, Sylvester R, Winter J, van Zijl K Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. Monogr Natl Cancer Inst. 11:1992;15-18.
34. DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako QA, Kukis DL, Meares CF, Yuan A, Welborn JL, DeNardo GL Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res. 17:1997;1735-1744.
35. DeNardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, DeNardo GL Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Anticancer Res. 18:1998;4011-4018. The authors describe the synergistic effect of Taxol and RIT in preclinical studies and the approach that applies the time/dose information to clinical protocol development.
36. Maraveyas A, Snook D, Hird V, Kosmas C, Meares CF, Lambert HE, Epenetos AA Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer. 73:1994;1067-1075.
37. Goldenberg DM, Kim EE, DeLand FH, Benett S, Primus FG Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res. 40:1980;2984-2992.
38. Juweid ME, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Goldenberg DM Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol. 14:1996;1209-1217.
39. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 85:1999;1828-1842.
40. Juweid ME, Swayne L, Sharkey RM, Dunn R, Rubin A, Herskovic T, Goldenberg DM Prospects of radioimmunotherapy in epithial ovarian cancer: results with 131I-labeled murine and humanized MN-14 anti-carcinoembryonic antigen (CEA) monoclonal antibodies. Gynecologic Oncology. 67:1997;259-271.
41. Juweid M, Rubin A, Hajjar G, Stein R, Sharkey RM, Goldenberg DM: First clinical results of combined radioimmunotherapy (RAIT) and chemotherapy (CH) in patients with medullary thyroid cancer [abstract]. In Proceedings of the Endocrine Society's 81st Annual Meeting: 1999 June 12-15; San Diego. Bethesda: Endocrine Society Press; 1999:434. The authors present the initial Phase I results of combining RIT with chemotherapy in medullary thyroid cancer.
42. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;. in press. G250 shows the highest reported uptake (%ID/g) of RIT to metastatic tumors in patients demonstrated to date (0.5233%ID/g).
43. Goodwin DA, Meares CF Editorial: pretargeted peptide imaging and therapy. Cancer Biotherapy Radiopharm. 14:1999;145-152. The authors present a comprehensive yet succinct review of the pretargeting approach to RIT.
44. ••] exploit the ultra-high-affinity interaction between biotin and streptavidin to deliver a radioisotope to a tumor and the clinical applications in lymphoma.
45. ••].
46. Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 14:1999;153-167. The authors describe pretargeting with a bispecific antibody (anti-CEA-anti-DTPA) followed by a radiolabeled bivalent hapten that forms a uniquely stable complex by cross-linking between the arms of the bispecific antibody on small-cell lung cancer and medullary thyroid tumors in patients.
47. Adams GP Improving the tumor specificity and retention of antibody-based molecules. In Vivo. 12:1998;11-22.
48. DeNardo SJ, DeNardo GL, DeNardo DG, Xiong CY, Shi XB, Winthrop MD, Kroger LA, Carter P Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res. 1999;. in press.
49. Kaminski MS, Vose J, Saleh M, Lister A, Knox S, Crowther D, Zelenetz AD, Colcher D, Wahl R A multicenter phase II study of iodine-131 anti-B1 antibody in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 90:1997;509.
50. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Stagg R, Kroll S, Tidmarsh G, Knox S, Vose J Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 92:1998;316.
51. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 55(suppl 23):1995;5921-5924.
52. 111I-2IT-BAD in patients with non-Hodgkin's lymphoma. J Nucl Med. 1999;. in press.